Circular Genomics

Circular Genomics is a biotechnology company revolutionizing precision psychiatry and neurology with its proprietary circular RNA platform. The company's mission is to make brain disorders measurable and manageable by developing blood-based diagnostic tests that offer a real-time view of brain biology, enabling personalized treatment decisions. Its lead product, MindLight™, is a commercially available test for predicting SSRI response in depression, and it is actively building a pipeline for Alzheimer's disease and other neurodegenerative conditions. Backed by exclusive IP licenses from leading research institutions and a distinguished scientific advisory board, Circular Genomics is positioned to address significant unmet needs in brain health.

A proprietary platform leveraging brain-derived circular RNA (circRNA) biomarkers. circRNAs are stable, brain-enriched molecules that cross the blood-brain barrier, providing a real-time, non-invasive window into brain biology for diagnostic and therapeutic applications.

Total raised: $3.5M

Circular Genomics faces competition from pharmacogenomic test providers in psychiatry (e.g., MindX Sciences) and a crowded field of protein-based blood biomarker developers in Alzheimer's (e.g., C2N, Fujirebio, Roche). Its differentiation lies in its pioneering focus on circRNAs, which offer stability and a direct reflection of dynamic brain biology, potentially providing unique insights into disease heterogeneity and treatment response.